TLPHTLPHHealthcare · Drug Manufacturers - Specialty & Generic

TLPH Stock Forecast: Talphera, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$0.80
+0.20% on the day

The 4 Wall Street analysts covering Talphera, Inc. hold a median 12-month price target of $3 — +274.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 17 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$41.6M
Ticker Nerd rank
34/ 100
Median analyst target
$3.00
Analysts covering
4
Revenue$0.0
Operating income−$3.9M
Net income−$4.3M
Free cash flow−$3.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−23.7%
1M
−25.8%
YTD
−29.7%
1Y
−40.2%
From 52W high
−45.5%
From 52W low
+11.3%
$0.72
$1.47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Talphera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
34/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
81
Momentum
67
Accruals
59
Revisions
51
Volatility
36
Issuance
34
Growth
33
Value
22
Quality
17

Size (81): Smaller than most of the companies we track.

Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TLPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26TLPHHigh $3.50Median $3.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $3.00Median $3.00High $3.50

The green dot is the last close — the median target sits +274.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 June 2026HC Wainwright & Co.AssumesBuy$3.00
30 Apr 2026WestPark CapitalInitiatesBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
21 Jan 2025HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
6 May 2024Maxim GroupInitiatesBuy—
7 Mar 2024HC Wainwright & Co.ReiteratesBuy—
22 Jan 2024HC Wainwright & Co.MaintainsBuy—
7 Dec 2023HC Wainwright & Co.ReiteratesBuy—
2 Oct 2023Alliance Global PartnersInitiatesBuy—
25 Sept 2023HC Wainwright & Co.MaintainsBuy—
18 Aug 2023HC Wainwright & Co.UpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TLPH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TLPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Talphera, Inc. returned −40.2% against +12.2% for the S&P 500, dividends included.

TLPH vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26TLPHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Talphera, Inc. (TLPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 88% of US stocks

Price / sales
41618.1×

Cheaper than 1% of US stocks

Price / book
2.3×

Cheaper than 35% of US stocks

EV / EBITDA
−3.3×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−1474700.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−143.4%

Higher than 10% of US stocks

Return on assets
−42.6%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Talphera, Inc. (TLPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Talphera, Inc. has a market value of $41.6M and an enterprise value of $43.1M.

  • Revenue in the twelve months to 30 June 2026: $1K.

  • Net income over the same four quarters: −$15.1M, a −1507600.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.27.

  • Free cash flow in the twelve months to 30 June 2026: −$12.3M.

  • Shares outstanding: 51.9M.

  • Trailing P/E: −2.3×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Talphera, Inc. employs 12 people — $83.3 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

TLPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TLPHTalphera, Inc.$41.6M34
CTORCitius Oncology, Inc.$50.9M42
AYTUAytu Biopharma, Inc.$28.6M96
SCYXSCYNEXIS, Inc.$28.3M36
RMTIRockwell Medical, Inc.$26.1M78
TXMDTherapeuticsMD, Inc.$22.1M82
CPHIChina Pharma Holdings, Inc.$21.5M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Talphera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TLPH news & analysis

Talphera, Inc. (TLPH) Q3 2026 Earnings Call Transcript

Seeking Alpha · 13 Nov 2026neutral

Seeking Alpha published the transcript of Talphera, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.

Why it matters — TLPH watchers can note the transcript’s publication, but the provided text does not describe company results or outlook.

Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 12 Nov 2026positive

Talphera reported that its pivotal NEPHRO study exceeds 80% power for the primary endpoint and that it submitted an FDA briefing document requesting a Sprint Meeting to discuss potentially closing enrollment based on the number of patients enrolled as of December 31, 2026. It also cited updated market research estimating peak nafamostat sales for CRRT above $200 million and reported $14.2 million in cash and investments at September 30, 2026.

Why it matters — The study update, market estimate, and reported cash position provide TLPH watchers information on clinical progress, commercial expectations, and available financial resources.

Talphera (TLPH) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research · 21 Sept 2026positive

Talphera (TLPH) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade could push the stock higher in the near term.

Why it matters — A Zacks upgrade to a Buy rating signals improved analyst sentiment about Talphera's near-term earnings outlook, which may be of interest to those following the stock.

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 3 Sept 2026neutral

Talphera, Inc. announced that company management will be presenting at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on September 3, 2026.

Why it matters — A company presentation at a major investor conference gives Talphera watchers an opportunity to hear management's latest updates on the company's development and commercialization activities.

FAQ

Frequently asked questions about TLPH stock

What is the TLPH stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Talphera, Inc. have a median 12-month price target of $3, with estimates ranging from $3 to $3.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLPH stock a buy right now?

Of the 4 analysts covering Talphera, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Talphera, Inc. 34 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLPH?

As at 17 Nov 2026, Talphera, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (81 of 100).

Will TLPH stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +274.3% from the last close, and Ticker Nerd's factor model ranks Talphera, Inc. 34 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLPH stock forecast for 2030?

No analyst covering Talphera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3.5 over the next 12 months.

How has TLPH stock performed over the past year?

Talphera, Inc. returned -40.2% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Talphera, Inc. do?

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings.

What is the latest news on TLPH?

The most recent item we track (Seeking Alpha, 13 Nov 2026): "Talphera, Inc. (TLPH) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Talphera, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.

Company

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for use in medically supervised settings. The company’s current portfolio centers on nafamostat product candidates and pre-filled syringe products designed for acute care environments, including hospital and procedural settings. Its lead program, Niyad, is a lyophilized formulation of nafamostat being studied as a regional anticoagulant for the extracorporeal circuit, while its broader pipeline includes pre-filled syringe products such as ephedrine and phenylephrine formulations. Talphera serves healthcare providers by targeting needs in high-acuity care where reliable, ready-to-use therapies can support treatment workflows. Headquartered in San Mateo, California, Talphera remains focused on specialty pharmaceuticals for medically supervised use.

CEO Mr. Vincent J. Angotti · 12 employees · United States · https://talphera.com